Payment overview · 2025
General Payments
$39.60
2 reported records · 2 companies
Healthcare provider profile · identity verified
Clara Stringer-Auld, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · BROOKLYN, NY · NPI 1578556866
Verified facts
What the public records show
CMS Open Payments records show Clara Stringer-Auld, M.D. received $39.60 in general payments during 2025 across 2 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 53.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Lokelma.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Lokelma by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $21.05 | 53.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.55 | 46.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $39.60 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $18.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 21 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
21 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1059 | 161 |
| Amlodipine Besylate | Amlodipine Besylate | 874 | 99 |
| Mirtazapine | Mirtazapine | 384 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 383 | 52 |
| Eliquis | Apixaban | 376 | 64 |
| Lisinopril | Lisinopril | 333 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 330 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 302 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 302 | 45 |
| Metformin Hcl | Metformin Hcl | 285 | 55 |
| Losartan Potassium | Losartan Potassium | 277 | 47 |
| Gabapentin | Gabapentin | 254 | 47 |
| Famotidine | Famotidine | 245 | 30 |
| Sertraline Hcl | Sertraline Hcl | 242 | 34 |
| Furosemide | Furosemide | 232 | 39 |
| Donepezil Hcl | Donepezil Hcl | 230 | 28 |
| Memantine Hcl | Memantine Hcl | 229 | 26 |
| Omeprazole | Omeprazole | 223 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 212 | 50 |
| Carvedilol | Carvedilol | 211 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 157 | 27 |
| Trazodone Hcl | Trazodone Hcl | 155 | 21 |
| Silodosin | Silodosin | 149 | 13 |
| Levetiracetam | Levetiracetam | 138 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 136 | 27 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 133 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 132 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 125 | 22 |
| Divalproex Sodium | Divalproex Sodium | 124 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 119 | 15 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 116 | 38 |
| Jardiance | Empagliflozin | 115 | 24 |
| Torsemide | Torsemide | 115 | 19 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 114 | 19 |
| Risperidone | Risperidone | 114 | 12 |
| Nifedipine Er | Nifedipine | 108 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 100 | suppressed |
| Januvia | Sitagliptin Phosphate | 98 | suppressed |
| Ssd | Silver Sulfadiazine | 98 | 38 |
| Olanzapine | Olanzapine | 97 | suppressed |
| Baclofen | Baclofen | 94 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 13 |
| Admelog Solostar | Insulin Lispro | 90 | 29 |
| Nystatin | Nystatin | 89 | 19 |
| Finasteride | Finasteride | 87 | 20 |
| Aripiprazole | Aripiprazole | 85 | suppressed |
| Lactulose | Lactulose | 84 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 81 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 80 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 79 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 67 | 12 |
| Atenolol | Atenolol | 65 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 65 | 14 |
| Alendronate Sodium | Alendronate Sodium | 64 | suppressed |
| Ezetimibe | Ezetimibe | 63 | 14 |
| Latanoprost | Latanoprost | 61 | 24 |
| Tradjenta | Linagliptin | 61 | suppressed |
| Simvastatin | Simvastatin | 59 | 17 |
| Glipizide Er | Glipizide | 56 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 53 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 51 | suppressed |
| Nitroglycerin | Nitroglycerin | 48 | suppressed |
| Spironolactone | Spironolactone | 48 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 47 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 47 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 47 | suppressed |
| Nystop | Nystatin | 44 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 43 | 11 |
| Lacosamide | Lacosamide | 43 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 42 | 41 |
| Glipizide | Glipizide | 39 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 38 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 13 |
| Potassium Chloride | Potassium Chloride | 37 | 17 |
| Timolol Maleate | Timolol Maleate | 37 | suppressed |
| Clonazepam | Clonazepam | 35 | 11 |
| Bupropion Hcl | Bupropion Hcl | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Calcitriol | Calcitriol | 33 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | 13 |
| Lamivudine | Lamivudine | 30 | suppressed |
| Tivicay | Dolutegravir Sodium | 30 | suppressed |
| Abacavir | Abacavir Sulfate | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Gemtesa | Vibegron | 29 | suppressed |
| Isentress | Raltegravir Potassium | 29 | suppressed |
| Gemfibrozil | Gemfibrozil | 28 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 28 | 14 |
| Labetalol Hcl | Labetalol Hcl | 28 | suppressed |
| Carbamazepine | Carbamazepine | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 23 | 13 |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 22 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 22 | suppressed |
| Procrit | Epoetin Alfa | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 21 | 12 |
| Lorazepam | Lorazepam | 21 | suppressed |
| Lumigan | Bimatoprost | 21 | suppressed |
| Rexulti | Brexpiprazole | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 18 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 17 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Paricalcitol | Paricalcitol | 16 | suppressed |
| Xifaxan | Rifaximin | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Rhopressa | Netarsudil Mesylate | 15 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $39.60 · 2 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR, LOKELMA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Lokelma play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error